CRISPR, CRSP and Therapeutics

Why CRISPR Therapeutics (CRSP) Soared on Friday?
We recently published a list of Shares of 10 Firms Soar on Friday. In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against other firms that soared on Friday.
CRISPR Therapeutics (NASDAQ:CRSP) Price Target Raised to $56.00
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target hoisted by Barclays from $55.00 to $56.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock.
CRISPR Therapeutics Stock Upgrade Following Analyst Reassessment
CRISPR Therapeutics (CRSP, Financials) stock rose 16.4% to $50.60 as of 10:10 a.m. GMT-5 on Friday, following an analyst upgrade. Citing pipeline advancements and possible catalysts, Evercore ISI analyst Liisa Bayko raised CRISpen Therapeutics from "In Line" to "Outperform.
CRISPR upped to outperform by Evercore on upcoming data
Evercore ISI has upgraded CRISPR (CRSP) to outperform from in line, citing upcoming data catalysts. Read more here.
Crispr Therapeutics upgraded to Outperform from In Line at Evercore ISI
Evercore ISI analyst Liisa Bayko upgraded Crispr Therapeutics (CRSP) to Outperform from In Line with a price target of $99, up from $60.
Evercore ISI Group Upgrades CRISPR Therapeutics (CRSP)
Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (NasdaqGM:CRSP) from In-Line to Outperform. Analyst Price Forecast Suggests 90.46% Upside As of January 28,
Q4 Earnings Surprise Greenlights CRISPR Therapeutics Stock Climb
CRISPR Therapeutics AG (CRSP) stock jumped over 9% this week after delivering strong Q4 2024 results ahead of schedule. The ...
Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future
Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...
CRISPR Therapeutics Q4 Earnings and Revenues Surpass Estimates
CRSP reports encouraging fourth-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is ...
CRISPR: From Discovery To Clinic—And Charting A Path Forward
No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...
Hosted on MSN2d
Crispr Therapeutics Faces Market Challenges Amidst BPCIA Biosimilar Risks
Crispr Therapeutics (CRSP) has disclosed a new risk, in the Innovation / R&D category. Crispr Therapeutics faces a significant business risk due ...
Stifel Nicolaus Sticks to Its Hold Rating for Crispr Therapeutics AG (CRSP)
Stifel Nicolaus analyst Benjamin Burnett maintained a Hold rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price ...
CRISPR upgraded to hold by TD Cowen on limited downside
TD Cowen has upgraded CRISPR Therapeutics (CRSP) to hold from sell, stating it now sees less downside to the stock. Read more ...